Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses

By sjmartinez • September 13, 2024

Lebwohl MG, Armstrong AW, Alexis AF, Lain EL, Jacobson AA. Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses. Dermatol Ther (Heidelb). 2024 Sep 12. doi: 10.1007/s13555-024-01264-3. Epub ahead of print. PMID: 39264399.

Tags: Alcohol, biologic therapy, Dermatology, IL-17 receptor A inhibitor, Obesity, plaque psoriasis, Publications, Tobacco

Related Posts

Global Healthcare Study on Psoriasis (GHSP): cohort profile and first findings

Maul JT, Fröhlich F, Nielsen ML, Maul LV, Torres T, Thyssen J, Armstrong A, Oon HH, Ji M, Kang X, Valenzuela F, Romiti R, Carvalho[...]

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. Zasocitinib[...]

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial

Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, Gordon KB, Sattar N, Puig L, Merola JF, Siu K, Wang R, Sun L, Leung A, Somani[...]